Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pruritus | D011537 | HP_0000989 | L29 | — | 2 | — | — | — | 2 |
Neurodermatitis | D009450 | — | L28.0 | — | 2 | — | — | — | 2 |
Psoriasis | D011565 | EFO_0000676 | L40 | — | 1 | — | — | — | 1 |
Lichen planus | D008010 | — | L43 | — | 1 | — | — | — | 1 |
Chronic urticaria | D000080223 | — | L50.8 | — | 1 | — | — | — | 1 |
Urticaria | D014581 | EFO_0005531 | L50 | — | 1 | — | — | — | 1 |
Prurigo | D011536 | — | L28.2 | — | 1 | — | — | — | 1 |
Systemic scleroderma | D012595 | EFO_0000717 | M34.0 | — | 1 | — | — | — | 1 |
Fibrosis | D005355 | — | — | — | 1 | — | — | — | 1 |
Lung diseases | D008171 | HP_0002088 | J98.4 | — | 1 | — | — | — | 1 |
Drug common name | VIXARELIMAB |
INN | vixarelimab |
Description | Vixarelimab (KPL-716) is a fully human monoclonal antibody that works by binding to the oncostatin M receptor β, thus inhibiting both interleukin 31 and oncostatin M. It is developed by Kiniksa Pharmaceuticals for prurigo nodularis.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4594341 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | W25GO3A75W (ChemIDplus, GSRS) |